Detalles de la búsqueda
1.
Comparison of the efficacy of first/secondgeneration EGFRtyrosine kinase inhibitors and osimertinib for EGFRmutant lung cancer with negative or low PDL1 expression.
Mol Clin Oncol;
20(6): 43, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38756869
2.
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.
In Vivo;
38(3): 1509-1511, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38688637
3.
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Target Oncol;
19(3): 423-433, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38613731
4.
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
Anticancer Res;
44(3): 1241-1245, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38423671
5.
A retrospective study of the efficacy of combined EGFRTKI plus VEGF inhibitor/cytotoxic therapy vs. EGFRTKI monotherapy for PDL1positive EGFRmutant nonsmall cell lung cancer: North Japan Lung Cancer Study Group 2202.
Oncol Lett;
26(2): 334, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427337
6.
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Sci Rep;
13(1): 10807, 2023 07 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402763
7.
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
Anticancer Res;
43(7): 3241-3246, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37351972
8.
Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumorinfiltrating CD68positive cell counts in patients with EGFRmutant nonsmall cell lung cancer.
Mol Clin Oncol;
18(5): 38, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37035471
9.
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice.
Thorac Cancer;
14(17): 1618-1623, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37101081
10.
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data.
JTO Clin Res Rep;
3(11): 100404, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36275911
11.
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).
Lung Cancer;
172: 1-8, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35952438
12.
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
Cancer Diagn Progn;
2(3): 324-329, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35530643
13.
Small cell lung cancer; recent advances of its biology and therapeutic perspective.
Respir Investig;
60(2): 197-204, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34896039
14.
Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.
Tumori;
107(6): 536-541, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34847814
15.
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors.
In Vivo;
35(3): 1687-1692, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910853
16.
Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression.
Cancer Diagn Progn;
1(3): 173-177, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35399317
17.
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy.
Diagnostics (Basel);
10(12)2020 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33255696
18.
Relationship between Patient Characteristics and the Timing of Provision of Explanation about DNAR to Patients with Advanced Lung Cancer.
Intern Med;
59(23): 2989-2994, 2020 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32759584
19.
Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
Pathol Oncol Res;
26(1): 327-333, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30232703
20.
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Anticancer Res;
39(12): 6887-6893, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31810958